Potential diagnostic applications of side chain oxysterols analysis in plasma and cerebrospinal fluid

Biochemical Pharmacology

Volumn 86, Issue 1, 2013, Pages 26-36

  Leoni, Valerio ^a   Caccia, Claudio ^a  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

Alzheimer's disease; Apolipoprotein E; Biomarker; Cholesterol; Mass spectrometry

Indexed keywords

24 HYDROXYCHOLESTEROL; 26 HYDROXYCHOLESTEROL; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; APOLIPOPROTEIN E4; CHOLESTEROL; CHOLESTEROL DERIVATIVE; OXYSTEROL; TAU PROTEIN; UNCLASSIFIED DRUG; 24-HYDROXYCHOLESTEROL; 27-HYDROXYCHOLESTEROL; BIOLOGICAL MARKER;

ALZHEIMER DISEASE; ARTICLE; BRAIN TUMOR; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID LEVEL; CEREBROVASCULAR ACCIDENT; CYTOTOXICITY; DEGENERATIVE DISEASE; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; HUNTINGTON CHOREA; LIPID ANALYSIS; LIPID BLOOD LEVEL; LIPOPROTEIN SYNTHESIS; MILD COGNITIVE IMPAIRMENT; MULTIINFARCT DEMENTIA; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; PARKINSON DISEASE; PRIORITY JOURNAL; ANIMAL; BLOOD; BRAIN; CEREBROSPINAL FLUID; METABOLISM; OXIDATION REDUCTION REACTION; PATHOLOGY; REVIEW;

ALZHEIMER DISEASE; ANIMALS; BIOLOGICAL MARKERS; BRAIN; CHOLESTEROL; HUMANS; HYDROXYCHOLESTEROLS; NEURODEGENERATIVE DISEASES; OXIDATION-REDUCTION;

EID: 84884310681     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.03.015     Document Type: Review

References (150)

1. Matthan NR, Raeini-Sarjaz M, Lichtenstein AH, Ausman LM, Jones PJ. Deuterium uptake and plasma cholesterol precursor levels correspond as methods for measurement of endogenous cholesterol synthesis in hypercholesterolemic women. Lipids 2000;35:1037-44.
2. Bloch KE. Sterol structure and membrane function. CRC Crit Rev Biochem 1983;14:47-92.
3. Kempen HJ, Glatz JF, Gevers Leuven JA, Van Der Voort HA, Katan MB. Serum lathosterol concentration is an indicator of whole-body cholesterol synthesis in humans. J Lipid Res 1988;29:1149-55.
4. Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem 2003;72:137-74. (Pubitemid 36930444)
5. Duane WC, Javitt NB. 27-hydroxycholesterol: production rates in normal human subjects. J Lipid Res 1999;40:1194-9. (Pubitemid 29328522)
6. Allen JA, Halverson-Tamboli RA, Rasenick MM. Lipid raft microdomains and neurotransmitter signalling. Nat Rev Neurosci 2007;8:128-40. (Pubitemid 46146951)
7. Koudinov AR, Koudinova NV. Essential role for cholesterol in synaptic plasticity and neuronal degeneration. FASEB J 2001;15:1858-60.
8. Dietschy JM, Turley SD. Thematic review series: brain lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J Lipid Res 2004;45:1375-97.
9. G. J. Snipe, U. Suter U. In: Bitmaan R, editor. Cholesterol and myelin. In Subcellular Biochemistry. Cholesterol: its function and metabolism in biology and medicine. New York 1997, pp. 173-204.
10. Pfrieger FW. Cholesterol homeostasis and function in neurons of the central nervous system. Cell Mol Life Sci 2003;60:1158-71. (Pubitemid 36791918)
11. Pfrieger FW, Ungerer N. Cholesterol metabolism in neurons and astrocytes. Prog Lipid Res 2011;50:357-71.
12. de Chaves EP, Narayanaswami V. Apolipoprotein E and cholesterol in aging and disease in the brain. Future Lipidol 2008;3:505-30.
13. Bu G. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat Rev Neurosci 2009;10:333-44.
14. Iuliano L. Pathways of cholesterol oxidation via non-enzymatic mechanisms. Chem Phys Lipids 2011;164:457-68.
15. Smith LL. Cholesterol autooxidation. Chem Phys Lipids 1987;44:87-125.
16. Russel DW. Oxysterol biosynthetic enzymes. Biochem Biophys Acta 2000;1529:126-35.
17. Meaney S, Bodin K, Diczfalusy U, Bjorkhem I. On the rate of translocation in vitro and kinetics in vivo of the major oxysterols in human circulation: critical importance of the position of the oxygen function. J Lipid Res 2002;43:2130-5. (Pubitemid 35471081)
18. Olkkonen VM, Beaslas O, Nissilä E. Oxysterols and their cellular effectors. Biomolecules 2012;2:76-103.
19. Björkhem I, Skrede S, Buchmann MS, East C, Grundy S. Accumulation of 7 alpha-hydroxy-4-cholesten-3-one and cholesta-4,6-dien-3-one in patients with cerebrotendinous xanthomatosis: effect of treatment with chenodeoxycholic acid. Hepatology 1987;7:266-71. (Pubitemid 17062715)
20. Zieden B, Kaminskas A, Kristenson M, Kucinskiene Z, Vesseby B, Olsson AG, et al. Increased plasma 7b-hydroxycholesterol concentrations in a population with high risk for cardiovascular disease. Arterioscler Thromb Vasc Biol 1999;19:967-71. (Pubitemid 29177344)
21. Lordan S, Mackrill JJ, O'Brien NM. Oxysterols and mechanisms of apoptotic signaling: implications in the pathology of degenerative diseases. J Nutr Biochem 2009;20:321-36.
22. Vejux A, Lizard G. Cytotoxic effects of oxysterols associated with human diseases: Induction of cell death (apoptosis and/or oncosis), oxidative and inflammatory activities, and phospholipidosis. Mol Aspects Med 2009;30:153-70.
23. Mintzer E, Charles G, Gordon S. Interaction of two oxysterols, 7-ketocholesterol and 25-hydroxycholesterol, with phosphatidylcholine and sphingomyelin in model membranes. Chem Phys Lipids 2010;163:586-93.
24. Royer MC, Lemaire-Ewing S, Desrumaux C, Monier S, Pais de Barros JP, Athias A, et al. 7-ketocholesterol incorporation into sphingolipid/ cholesterolenriched (lipid raft) domains is impaired by vitamin E: a specific role for alpha-tocopherol with consequences on cell death. J Biol Chem 2009;284:15826-34.
25. Kahn E, Baarine M, Dauphin A, Ragot K, Tissot N, Seguin A, et al. Impact of 7- ketocholesterol and very long chain fatty acids on oligodendrocyte lipid membrane organization: evaluation via LAURDAN and FAMIS spectral image analysis. Cytometry A 2011;79:293-305.
26. Ragot K, Delmas D, Athias A, Nury T, Baarine M, Lizard G. a-Tocopherol impairs 7-ketocholesterol-induced caspase-3-dependent apoptosis involving GSK-3 activation and Mcl-1 degradation on 158 N murine oligodendrocytes. Chem Phys Lipids 2011;164:469-78.
27. Barnett MH, Prineas JW. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol 2004;55:458-68. (Pubitemid 38391962)
28. Diestel A, Aktas O, Hackel D, Hake I, Meier S, Raine CS, et al. Activation of microglial poly(ADP-ribose)-polymerase-1 by cholesterol breakdown products during neuroinflammation: a link between demyelination and neuronal damage. J Exp Med 1981;2003:729-40.
29. Leoni V, Lutjohann D, Mastermann T. Levels of 7-oxocholesterol in cerebrospinal fluid in patients with multiple sclerosis are more than a thousand times lower than reported. J Lipid Res 2005;46:191-5. (Pubitemid 40271081)
30. Lütjohann D, Breuer O, Ahlborg G, Nennesmo I, Siden A, Diczfalusy U, et al. Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation. Proc Natl Acad Sci USA 1996;93:9799-804. (Pubitemid 26296689)
31. Xie C, Lund EG, Turley SD, Russell DW, Dietschy JM. Quantitation of two pathways for cholesterol excretion from the brain in normal mice and mice with neurodegeneration. J Lipid Res 2003;44:1780-9. (Pubitemid 37185890)
32. Lund EO, Andersson O, Zheng J, Babiker A, Ahlborg G, Diczfalusy U, et al. Importance of a novel oxidative mechanism for elimination of intracellular cholesterol in humans. Artherioscler Thromb Vasc Biol 1996;16:208-12. (Pubitemid 26056238)
33. Abildayeva K, Jansen PJ, Hirsch-Reinshagen V, Bloks VW, Bakker AH, Ramaekers FC, et al. 24(S)-hydroxycholesterol participates in a liver X receptorcontrolled pathway in astrocytes that regulates apolipoprotein E-mediated cholesterol efflux. J Biol Chem 2006;281:12799-808. (Pubitemid 43855372)
34. Wang N, Yvan-Charvet L, Lü tjohann D, Mulder M, Vanmierlo T, Kim TW, et al. ATP-binding cassette transporters G1 and G4 mediate cholesterol and desmosterol efflux to HDL and regulate sterol accumulation in the brain. FASEB J 2008;22:1073-82. (Pubitemid 351519962)
35. Kotti TJ, Ramirez DM, Pfeiffer BE, Huber KM, Russell DW. Brain cholesterol turnover required for geranylgeraniol production and learning in mice. Proc Natl Acad Sci USA 2006;103:3869-74. (Pubitemid 43376647)
36. Brown AJ, Oxysterols Jessup W. Sources, cellular storage and metabolism, and new insights into their roles in cholesterol homeostasis. Mol Aspects Med 2009;30:111-22.
37. Upston JM, Niu X, Brown AJ, Mashima R, Wang H, Senthilmohan R, et al. Disease stage-dependent accumulation of lipid and protein oxidation products in human atherosclerosis. Am J Pathol 2002;160:701-10. (Pubitemid 34160348)
38. Karuna R, Holleboom AG, Motazacker MM, Kuivenhoven JA, Frikke-Schmidt R, Tybjaerg-Hansen A, et al. Plasma levels of 27-hydroxycholesterol in humans and mice with monogenic disturbances of high density lipoprotein metabolism. Atherosclerosis 2011;214:448-55.
39. Babiker A, Dzeletovic S, Wiklund B, Pettersson N, Salonen J, Nyyssönen K, et al. Patients with atherosclerosis may have increased circulating levels of 27-hydroxycholesterol and cholestenoic acid. Scand J Clin Lab Invest 2005;65:365-75.
40. Zhang J, Akwa Y, el-Etr M, Baulieu EE, Sjö vall J. Metabolism of 27-, 25- and 24- hydroxycholesterol in rat glial cells and neurons. Biochem J 1997;322:175- 84. (Pubitemid 27095538)
41. Heverin M, Bogdanovic N, Lutjohann D, Bayer T, Pikuleva I, Bretillon L, et al. Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer's disease. J Lipid Res 2004;45:186-93. (Pubitemid 38180529)
42. Shafaati M, Marutle A, Pettersson H, Lövgren-Sandblom A, Olin M, Pikuleva I, et al. Marked accumulation of 27-hydroxycholesterol in the brains of Alzheimer's patients with the Swedish APP 670/671 mutation. J Lipid Res 2011;52:1004-10.
43. Brown J, Theisler C, Silberman S, Magnuson D, Gottardi-Littell N, Lee JM, et al. Differential expression of cholesterol hydroxylases in alzheimer's disease. J Biol Chem 2004;279:34674-81. (Pubitemid 39318097)
44. Leoni V, Masterman T, Patel P, Meaney S, Diczfalusy U, Björkhem I. Side chain oxidized oxysterols in cerebrospinal fluid and the integrity of blood-brain and blood-cerebrospinal fluid barriers. J Lipid Res 2003;44:793-9. (Pubitemid 37279681)
45. Heverin M, Meaney S, Lü tjohann D, Diczfalusy U, Wahren J, Björkhem I. Crossing the barrier: net flux of 27-hydroxycholesterol into the human brain. J Lipid Res 2005;46:1047-52.
46. Meaney S, Heverin M, Panzenboeck U, Ekström L, Axelsson M, Andersson U, et al. Novel route for elimination of brain oxysterols across the blood-brain barrier: conversion into7alpha-hydroxy-3-oxo-4-cholestenoic acid. J Lipid Res 2007;48:944-51. (Pubitemid 46557899)
47. Mateos L, Ismail MA, Gil-Bea FJ, Leoni V, Winblad B, Björkhem I, et al. Upregulation of brain renin angiotensin system by 27-hydroxycholesterol in Alzheimer's disease. J Alzheimers Dis 2011;24:669-79.
48. Blennow K, De Leon MJ, Zetterberg H. Alzheimer's disease. Lancet 2006;368:387-403. (Pubitemid 44108123)
49. Di Paolo G, Kim TW. Linking lipids to Alzheimer's disease: cholesterol and beyond. Nat Rev Neurosci 2011;12:284-96.
50. Howland DS, Trusko SP, Savage MJ, Reaume AG, Lang DM, Hirsch JD, et al. Modulation of secreted beta-amyloid precursor protein and amyloid betapeptide in brain by cholesterol. J Biol Chem 1998;273:16576-82. (Pubitemid 28311445)
51. Frears ER, Stephens DJ, Walters CE, Davies H, Austen BM. The role of cholesterol in the biosynthesis of beta-amyloid. Neuroreport 1999;10:1699-705.
52. Bodovitz S, Klein WL. Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein. J Biol Chem 1996;271:4436-40.
53. Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak- Vance MA, Joo SH, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993;43:1467-72. (Pubitemid 23230526)
54. Jack Jr CR, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, et al. Alzheimer's Disease Neuroimaging Initiative. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009;132:1355-65.
55. Jack Jr CR, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;9:119-28.
56. Nicholson AM, Ferreira A. Increased membrane cholesterol might render mature hippocampal neurons more susceptible to beta-amyloid-induced calpain activation and tau toxicity. J Neurosci 2009;29: 4640-51.
57. Strittmatter WJ, Saunders AM, Goedert M, Weisgraber KH, Dong LM, Jakes R, et al. Isoform-specific interactionsof apolipoprotein E with microtubuleassociated protein tau: implications for Alzheimer disease. Proc Natl Acad Sci USA 1994;91:11183-86.
58. Refolo LM, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, Tint GS, et al. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 2000;7:321-31.
59. Shie FS, Jin LW, Cook DG, Leverenz JB, LeBoeuf RC. Diet-induced hypercholesterolemia enhances brain A beta accumulation in transgenic mice. Neuroreport 2002;13:455-9. (Pubitemid 34293189)
60. Canepa E, Borghi R, Vina J, Traverso N, Gambini J, Domenicotti C, et al. Cholesterol and amyloid-b: evidence for a cross-talk between astrocytes and neuronal cells. J Alzheimers Dis 2011;25(4):645-53.
61. Kojro E, Gimpl G, Lammich S, Marz W, Fahrenholz F. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha -secretase ADAM 10. Proc Natl Acad Sci USA 2001;98:5815-20. (Pubitemid 32435725)
62. Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci USA 1998;95:6460-4. (Pubitemid 28249035)
63. Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, et al. Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci USA 2001;98:5856-61. (Pubitemid 32435732)
64. Ehehalt R, Keller P, Haass C, Thiele C, Simons K. Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J Cell Biol 2003;160:113-23. (Pubitemid 36091721)
65. Xiong H, Callaghan D, Jones A, Walker DG, Lue LF, Beach TG, et al. Cholesterol retention in Alzheimer's brain is responsible for high beta- and gammasecretase activities and Abeta production. Neurobiol Dis 2008;29:422-37.
66. Ullrich C, Pirchl M, Humpel C. Hypercholesterolemia in rats impairs the cholinergic system and leads to memory deficits. Mol Cell Neurosci 2010;45:408-17.
67. Glockner F, Meske V, Lutjohann D, Ohm TG. Dietary cholesterol and its effect on tau protein: a study in apolipoprotein E-deficient and P301L human tau mice. J Neuropathol Exp Neurol 2011;70:292-301.
68. Rahman A, Akterin S, Flores-Morales A, Crisby M, Kivipelto M, Schultzberg M, et al. High cholesterol diet induces tau hyperphosphorylation in apolipoprotein E deficient mice. FEBS Lett 2005;579:6411-6. (Pubitemid 41612160)
69. Kivipelto M, Solomon A. Cholesterol as a risk factor for Alzheimer's disease - epidemiological evidence. Acta Neurol Scand Suppl 2006;185:50-7. (Pubitemid 44015225)
70. Solomon A, Kivipelto M, Wolozin B, Zhou J, Whitmer RA. Midlife serum cholesterol and increased risk of Alzheimer's and vascular dementia three decades later. Dement Geriatr Cogn Disord 2009;28:75-80.
71. Solomon A, Leoni V, Kivipelto M, Besga A, Oksengard AR, Julin P, et al. Plasma levels of 24S-hydroxycholesterol reflect brain volumes in patients without objective cognitive impairment but not in those with Alzheimer's disease. Neurosci Lett 2009;462:89-93.
72. Stewart R, White LR, Xue QL, Launer LJ. Twenty-six-year change in total cholesterol levels and incident dementia: the Honolulu-Asia Aging Study. Arch Neurol 2007;64:103-7. (Pubitemid 46072431)
73. Prasanthi JR, Huls A, Thomasson S, Thompson A, Schommer E, Ghribi O. Differential effects of 24-hydroxycholesterol and 27-hydroxycholesterol onbeta-amyloid precursor protein levels and processing in human neuroblastomaSH- SY5Y cells. Mol Neurodegener 2009;4:1.
74. Famer D, Meaney S, Mousavi M, Nordberg A, Bjorkhem I, Crisby M. Regulation of alpha- and betasecretase activity by oxysterols: cerebrosterol stimulates processing of APP via the alpha-secretase pathway. Biochem Biophys Res Commun 2007;359:46-50. (Pubitemid 46844819)
75. Dasari B, Prasanthi JR, Marwarha G, Singh BB, Ghribi O. The oxysterol 27- hydroxycholesterol increases b-amyloid and oxidative stress in retinal pigment epithelial cells. BMC Ophthalmol 2010; http://dx.doi.org/10.1186/ 1471-2415-10-22, http://www.biomedcentral.com/1471-2415/10/22.
76. Prasanthi JR, Larson T, Schommer J, Ghribi O. Silencing GADD153/CHOP gene expression protects against Alzheimer's disease-like pathology induced by 27-hydroxycholesterol in rabbit hippocampus. PLoS ONE 2011;6:e26420. http://dx.doi.org/10.1371/journal.pone.0026420.
77. Björkhem I, Cedazo-Minguez A, Leoni V, Meaney S. Oxysterols and neurodegenerative diseases. Mol Aspects Med 2009;30:171-9.
78. Leoni V, Caccia C. Oxysterols as biomarkers in neurodegenerative diseases. Chem Phys Lipids 2011;164:515-24.
79. Leoni V, Caccia C. 24S-hydroxycholesterol in plasma: A marker of cholesterol turnover in neurodegenerative diseases. Biochimie 2012; pii:S0300- 9084(12)00385-9, http://dx.doi.org/10.1016/j.biochi.2012.09.025 [epub ahead of print].
80. Björkhem I. Crossing the barrier, oxysterols as cholesterol transporters and metabolic modulators in the brain. J Intern Med 2006;260:493-508. (Pubitemid 44772369)
81. Bretillon L, Lutjohann D, Stahle L, Widhe T, Bindl L, Eggersten G, et al. Plasma levels of 24S-hydroxycholesterol reflect the balance between cerebral production and hepatic metabolism and are inversely related to body surface. J Lipid Res 2000;41:840-5. (Pubitemid 30314140)
82. Bretillon L, Siden A, Wahlund LO, Lü tjohann D, Minthon L, Crisby M, et al. Plasma levels of 24S-hydroxycholesterol in patients with neurological diseases. Neurosci Lett 2000;293:87-90.
83. Kolsch H, Heun R, Kerksiek A, Bergmann KV, Maier W, Lutjohann D. Altered levels of plasma 24S- and 27-hydroxycholesterol in demented patients. Neurosci Lett 2004;368:303-8. (Pubitemid 39214973)
84. Teunissen CE, Dijkstra CD, Polman CH, Hoogervorst EL, von Bergmann K, Lü tjohann D. Decreased levels of the brain specific 24S-hydroxycholesterol and cholesterol precursors in serum of multiple sclerosis patients. Neurosci Lett 2003;347:159-62. (Pubitemid 37271941)
85. Teunissen CE, Lü tjohann D, von Bergmann K, Verhey F, Vreeling F, Wauters A, et al. Combination of serum markers related to several mechanisms in Alzheimer's disease. Neurobiol Aging 2003;24:893-902. (Pubitemid 36962973)
86. Leoni V, Masterman T, Diczfalusy U, De Luca G, Hillert J, Björkhem I. Changes in human plasma levels of 24S-hydroxycholesterol during progression of multiple sclerosis. Neurosci Lett 2002;331:163-6.
87. Leoni V, Mariotti C, Tabrizi SJ, Valenza M, Wild EJ, Henley SM, et al. Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington's disease. Brain 2008;131:2851-9.
88. Leoni V, Mariotti C, Nanetti L, Salvatore E, Squitieri F, Bentivoglio AR, et al. Whole body cholesterol metabolism is impaired in Huntington's disease. Neurosci Lett 2011;494:245-9.
89. Danylaite Karrenbauer V, Leoni V, Lim ET, Giovannoni G, Ingle GT, Sastre- Garriga J, et al. Plasma cerebrosterol and magnetic resonance imaging measures in multiple sclerosis. Clin Neurol Neurosurg 2006;108: 456-60. (Pubitemid 43744509)
90. Qureischie H, Heun R, Lü tjohann D, Popp J, Jessen F, Ledschbor-Frahnert C, et al. CETP polymorphisms influence cholesterol metabolism but not Alzheimer's disease risk. Brain Res 2008;1232:1-6.
91. Besga A, Cedazo-Minguez A, Kareholt I, Solomon A, Björkhem I, Winblad B, et al. Differences in brain cholesterol metabolism and insulin in two subgroups of patients with different CSF biomarkers but similar white matter lesions suggest different pathogenic mechanisms. Neurosci Lett 2012;510:121-6.
92. Zuliani G, Donnorso MP, Bosi C, Passaro A, Dalla Nora E, Zurlo A, et al. Plasma 24S-hydroxycholesterol levels in elderly subjects with late onset Alzheimer's disease or vascular dementia: a case-control study. BMC Neurol 2011;11:121.
93. Bjorkhem I, Meaney S, Diczfalusy U. Oxysterols in human circulation: which role do they have. Curr Opin Lipidol 2002;13:247-53. (Pubitemid 34592280)
94. Hughes TM, Rosano C, Evans RW, Kuller LH. Brain cholesterol metabolism, oxysterols, and dementia. J Alzheimers Dis 2012; http://dx.doi.org/10.3233/ JAD-2012-121585 [epub ahead of print].
95. Lü tjohann D, Papassotiropoulos A, Björkhem I, Locatelli S, Bagli M, Oehring RD, et al. Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients. J Lipid Res 2000;41:195-8. (Pubitemid 30117859)
96. Popp J, Lewczuk P, Kö lsch H, Meichsner S, Maier W, Kornhuber J, et al. Cholesterol metabolism is associated with soluble amyloid precursor protein production in Alzheimer's disease. J Neurochem 2012;123:310-6.
97. Popp J, Meichsner S, Kö lsch H, Lewczuk P, Maier W, Kornhuber J, et al. Cerebral and extracerebral cholesterol metabolism and CSF markers of Alzheimer's Disease. Biochem Pharmacol 2013; [epub ahead of print]: http://www.sciencedirect.com/science/article/pii/S0006295212007939.
98. Hughes TM, Kuller LH, Lopez OL, Becker JT, Evans RW, Sutton-Tyrrell K, et al. Markers of cholesterol metabolism in the brain show stronger associations with cerebrovascular disease than Alzheimer's disease. J Alzheimers Dis 2012;30:53-61.
99. Porter FD, Scherrer DE, Lanier MH, Langmade SJ, Molugu V, Gale SE, et al. Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Sci Transl Med 2010;2:56ra81.
100. Jiang X, Sidhu R, Porter FD, Yanjanin NM, Speak AO, te Vruchte DT, et al. A sensitive and specific LC-MS/MS method for rapid diagnosis of Niemann-Pick C1 disease from human plasma. J Lipid Res 2011;52:1435-45.
101. Farez MF, Quintana FJ, Gandhi R, Izquierdo G, Lucas M, Weiner HL. Toll-like receptor 2 and poly(ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE. Nat Immun 2009;10:958-64.
102. Björkhem I, Lövgren-Sandblom A, Piehl F, Khademi M, Pettersson H, Leoni V, et al. High levels of 15-oxygenated steroids in circulation of patients with multiple sclerosis: fact or fiction. J Lipid Res 2011;52:170-4.
103. Goizet C, Boukhris A, Durr A, Beetz C, Truchetto J, Tesson C, et al. CYP7B1 mutations in pure and complex forms of hereditary spastic paraplegia type 5. Brain 2009;132:1589-600.
104. Schü le R, Brandt E, Karle KN, Tsaousidou M, Klebe S, Klimpe S, et al. Analysis of CYP7B1 in non-consanguineous cases of hereditary spastic paraplegia. Neurogenetics 2009;10:97-104.
105. Tsaousidou MK, Ouahchi K, Warner TT, Yang Y, Simpson MA, Laing NG, et al. Sequence alterations within CYP7B1 implicate defective cholesterol homeostasis in motor-neuron degeneration. Am J Hum Genet 2008;82:510-5.
106. Schü le R, Siddique T, Deng HX, Yang Y, Donkervoort S, Hansson M, et al. Marked accumulation of 27-hydroxycholesterol inSPG5 patients with hereditary spastic paresis. J Lipid Res 2010;51:819-23.
107. Ellis E, Axelson M, Abrahamsson A, Eggertsen G, Thö rne A, Nowak G, et al. Feedback regulation of bile acid synthesis in primary human hepatocytes: evidence that CDCA is the strongest inhibitor. Hepatology 2003;38: 930-8. (Pubitemid 37221676)
108. Bjorkhem I, Reihner E, Angelin B, Ewerth S, Akerlund JE, Einarsson K. On the possible use of the serum level of 7 alpha-hydroxycholesterol as a marker for increased activity of the cholesterol 7 alpha-hydroxylase in humans. J Lipid Res 1987;28:889-94. (Pubitemid 17143370)
109. Panzenboeck U, Andersson U, Hansson M, Sattler W, Meaney S, Björkhem I. On the mechanism of cerebral accumulation of cholestanol in patients with cerebrotendinous xanthomatosis. J Lipid Res 2007;48:1167-74. (Pubitemid 46708684)
110. Teunissen CE, De Vente J, von Bergmann K, Bosma H, van Boxtel MP, De Bruijn C, et al. Serum cholesterol, precursors and metabolites and cognitive performance in an aging population. Neurobiol Aging 2003;24:147-55. (Pubitemid 35454151)
111. van den Kommer TN, Dik MG, Comijs HC, Lü tjohann D, Lips P, Jonker C, et al. The role of extracerebral cholesterol homeostasis and ApoE e4 in cognitive decline. Neurobiol Aging 2012;33:17-28.
112. Leoni V. Oxysterols as markers of neurological disease-a review. Scand J Clin Lab Invest 2009;69:22-5.
113. Leoni V, Masterman T, Mousavi FS, Wretlind B, Wahlund LO, Diczfalusy U, et al. Diagnostic use of cerebral and extracerebral oxysterols. Clin Chem Lab Med 2004;42:186-91. (Pubitemid 38401447)
114. Leoni V, Shafaati M, Salomon A, Kivipelto M, Björkhem I, Wahlund LO. Are the CSF levels of 24S-hydroxycholesterol a sensitive biomarker for mild cognitive impairment. Neurosci Lett 2006;397:83-7. (Pubitemid 43340464)
115. Shafaati M, Solomon A, Kivipelto M, Björkhem I, Leoni V. Levels of ApoE in cerebrospinal fluid are correlated with Tau and 24S-hydroxycholesterol in patients with cognitive disorders. Neurosci Lett 2007;425:78-82. (Pubitemid 47410361)
116. Papassotiropoulos A, Lü tjohann D, Bagli M, Locatelli S, Jessen F, Buschfort R, et al. 24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia. J Psychiatr Res 2002;36:27-32. (Pubitemid 34037845)
117. Schönknecht P, Lü tjohann D, Pantel J, Bardenheuer H, Hartmann T, von Bergmann K, et al. Cerebrospinal fluid 24S-hydroxycholesterol is increased in patients with Alzheimer's disease compared to healthy controls. Neurosci Lett 2002;324:83-5. (Pubitemid 34442684)
118. Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008;57:178-201.
119. Reiber H. Dynamics of brain-specific protein in cerebrospinal fluid. Clin Chim Acta 2001;310:173-86. (Pubitemid 32728347)
120. Kermode AG, Tofts PS, Thompson AJ, MacManus DG, Rudge P, Kendall BE, et al. Heterogeneity of blood-brain barrier changes in multiple sclerosis: an MRI study with gadolinium-DTPA enhancement. Neurology 1990;40: 229-35. (Pubitemid 20099429)
121. Farrall AJ, Wardlaw JM. Blood-brain barrier: ageing and microvascular disease-systematic review and meta-analysis. Neurobiol Aging 2009; 30:337-52.
122. Vanmierlo T, Popp J, Kolsch H, Friedrichs S, Jessen F, Stoffel-Wagner B, et al. The plant sterol brassicasterol as additional CSF biomarker in Alzheimer's disease. Acta psychiatric Scandinavica 2011;124:184-92.
123. Chalbot S, Zetterberg H, Blennow K, Fladby T, Andreasen N, Grundke-Iqbal I, et al. Blood-cerebrospinal fluid barrier permeability in Alzheimer's disease. J Alzheimers Dis 2011;25:505-15.
124. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease. Mol Chem Neuropathol 1995;26:231-45. (Pubitemid 26002016)
125. Wahlund LO, Blennow K. Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients. Neurosci Lett 2003;339: 99-102. (Pubitemid 36254786)
126. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010;6:131-44.
127. Jack Jr CR, Dickson DW, Parisi JE, Xu YC, Cha RH, O'Brien PC, et al. Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology 2002;58:750-7. (Pubitemid 34211554)
128. Jagust WJ, Zheng L, Harvey DJ, Mack WJ, Vinters HV, Weiner MW, et al. Neuropathological basis of magnetic resonance images in aging and dementia. Ann Neurol 2008;63:72-80. (Pubitemid 351240553)
129. Vemuri P, Whitwell JL, Kantarci K, Josephs KA, Parisi JE, Shiung MS, et al. Antemortem MRI based STructural Abnormality iNDex (STAND)-scores correlate with postmortem Braak neurofibrillary tangle stage. Neuroimage 2008;42:559-67.
130. Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology 2009;73:287-93.
131. Holtzman DM, Bales KR, Wu S, Bhat P, Parsadanian M, Fagan AM, et al. Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's disease. J Clin Invest 1999;103:R15-21. (Pubitemid 29152639)
132. Harris FM, Brecht WJ, Xu Q, Tesseur I, Kekonius L, Wyss-Coray T, et al. Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease- like neurodegeneration and behavioral deficits in transgenic mice. Proc Natl Acad Sci USA 2003;100:10966-71. (Pubitemid 37140136)
133. Tesseur I, Van Dorpe J, Spittaels K, Van den Haute C, Moechars C, Van Leuven F. Expression of human apolipoprotein E4 in neurons causes hyperphosphorylation of protein tau in the brains of transgenic mice. Am J Pathol 2000;156:951-64. (Pubitemid 30626953)
134. Tiraboschi P, Hansen LA, Masliah E, Alford M, Thal LJ, Corey-Bloom J. Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease. Neurology 2004;62:1977-83. (Pubitemid 38738207)
135. Kok E, Haikonen S, Luoto T, Huhtala H, Goebeler S, Haapasalo H, et al. Apolipoprotein E-dependent accumulation of Alzheimer disease-related lesions begins in middle age. Ann Neurol 2009;65:650-7.
136. Rapp A, Gmeiner B, Huttinger M. Implication of apoE isoforms in cholesterol metabolism by primary rat hippocampal neurons and astrocytes. Biochimie 2006;88:473-83. (Pubitemid 43867898)
137. Gong JS, Kobayashi M, Hayashi H, Zou K, Sawamura N, Fujita SC, et al. Apolipoprotein E (ApoE) isoform-dependent lipid release from astrocytes prepared from human ApoE3 and ApoE4 knock-in mice. J Biol Chem 2002;277:29919-26.
138. Vedhachalam C, Narayanaswami V, Neto N, Forte TM, Phillips MC, Lund-Katz S, et al. The C-terminal lipid-binding domain of apolipoprotein E is a highly efficient mediator of ABCA1-dependent cholesterol efflux that promotes the assembly of high-density lipoproteins. Biochemistry 2007;46: 2583-93. (Pubitemid 46417902)
139. Leoni V. The effect of apolipoprotein E (ApoE) genotype on biomarkers of amyloidogenesis, tau pathology and neurodegeneration in Alzheimer's disease. Clin Chem Lab Med 2011;49:375-83.
140. Serrano-Pozo A, Vega GL, Lü tjohann D, Locascio JJ, Tennis MK, Deng A, et al. Effects of simvastatin on cholesterol metabolism and Alzheimer disease biomarkers. Alzheimer Dis Assoc Disord 2010;24:220-6.
141. Kim WS, Rahmanto AS, Kamili A, Rye KA, Guillemin GJ, Gelissen IC, et al. Role of ABCG1 and ABCA1 in regulation of neuronal cholesterol efflux to apolipoprotein E discs and suppression of amyloid-beta peptide generation. J Biol Chem 2007;282:2851-61. (Pubitemid 47084333)
142. Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer's disease. Neuron 2009;63:287-303.
143. Kö lsch H, Lü tjohann D, Tulke A, Björkhem I, Rao ML. The neurotoxic effect of 24-hydroxycholesterol on SH-SY5Y human neuroblastoma cells. Brain Res 1999;818:171-5. (Pubitemid 29227299)
144. Yamanaka K, Saito Y, Yamamori T, Urano Y, Noguchi N. 24(S)- hydroxycholesterol induces neuronal cell death through necroptosis, a form of programmed necrosis. J Biol Chem 2011;286:24666-73.
145. Gamba P, Leonarduzzi G, Tamagno E, Guglielmotto M, Testa G, Sottero B, et al. Interaction between24-hydroxycholesterol, oxidative stress, and amyloid-b in amplifying neuronal damage in Alzheimer's disease: three partners in crime.
146. Koschack J, Lü tjohann D, Schmidt-Samoa C, Irle E. Serum 24S-hydroxycholesterol and hippocampal size in middle-aged normal individuals. Neurobiol Aging 2009;30:898-902.
147. Papassotiropoulos A, Lü tjohann D, Bagli M, Locatelli S, Jessen F, Rao ML, et al. Plasma 24S-hydroxycholesterol: a peripheral indicator of neuronal degen- eration and potential state marker for Alzheimer's disease. Neuroreport 2000;11:1959-62.
148. Iuliano L, Monticolo R, Straface G, Spoletini I, Gianni W, Caltagirone C, et al. Vitamin E and enzymatic/oxidative stress-driven oxysterols in amnestic mild cognitive impairment subtypes and Alzheimer's disease. J Alzheimers Dis 2010;21:1383-92.
149. Weiner MF, Vega GL, Diaz-Arrastia R, Moore C, Madden C, Hudak A. Lütjohann D. Plasma 24S-hydroxycholesterol and other oxysterols in acute closed head injury. Brain Inj 2008;22:611-5. (Pubitemid 351877856)
150. Leoni V, Strittmatter L, Zorzi G, Zibordi F, Dusi S, Garavaglia B, et al. Metabolic consequences of mitochondrial coenzyme A deficiency in patients with PANK2 mutations. Mol Genet Metab 2012;105:463-71.